Withaferin A, a natural compound with anti-tumor activity, is a potent inhibitor of transcription factor C/EBPβ

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• Transcription factor Myb deregulation is implicated in leukemia and other cancers.
• Myb and its partners are critical targets for anti-cancer drug development.
• Withaferin A (WFA) is a natural compound with demonstrated anti-tumor properties.

Purpose of the Study:

• To identify inhibitors of Myb-dependent transcription using a myeloid Myb-reporter cell line.
• To elucidate the mechanism by which WFA inhibits Myb-dependent transcription.
• To investigate WFA's potential as a therapeutic agent targeting Myb-cooperating factors.

Main Methods:

• Utilized a myeloid Myb-reporter cell line to screen for Myb transcriptional inhibitors.
• Performed biochemical assays to analyze the inhibitory effects of WFA on Myb and C/EBPβ.
• Investigated the molecular mechanism of WFA action, including covalent modification and protein-protein interaction disruption.

Main Results:

• Identified Withaferin A (WFA) as an inhibitor of Myb-dependent transcription.
• Demonstrated that WFA is a more potent inhibitor of C/EBPβ than Myb.
• Showed that WFA covalently modifies C/EBPβ at specific cysteine residues, disrupting its interaction with the co-activator p300.
• Confirmed C/EBPβ as a direct target of WFA and highlighted p300's role as a crucial co-activator.

Conclusions:

• WFA's potent inhibition of C/EBPβ suggests this interaction is key to its anti-tumor activity.
• C/EBPβ is identified as a novel direct target of WFA.
• The findings highlight the therapeutic potential of targeting C/EBPβ and its co-activator p300 in cancer treatment.